Assyro AI

FDA Orange Book · active-ingredient family

Colchicine

Colchicine is approved as 4 brand and 17 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:LODOCO · NDA 215727

4

Brand (NDA)

17

Generics (ANDA)

41

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule, solution, tablet

ProductApplicantApplicationTEApproved
LODOCORLDAGEPHA PHARMA FZNDA 215727Jun 16, 2023
GLOPERBARLDSCILEX PHARMSNDA 210942Jan 30, 2019
MITIGARERLDHIKMA INTL PHARMSNDA 204820ABSep 26, 2014
COLCRYSRLDTAKEDA PHARMS USANDA 022352Jul 29, 2009

Generic (ANDA) products (17)

ProductApplicantApplicationTEApproved
COLCHICINEMICRO LABSANDA 212880ABFeb 17, 2026
COLCHICINEMACLEODS PHARMS LTDANDA 210633ABFeb 13, 2026
COLCHICINEANNORA PHARMAANDA 217620ABApr 29, 2024
COLCHICINEAUROBINDO PHARMA LTDANDA 215463ABApr 29, 2024
COLCHICINEGRANULESANDA 210757ABApr 29, 2024
COLCHICINESTRIDES PHARMAANDA 209173ABMar 10, 2022
COLCHICINEAUROBINDO PHARMA LTDANDA 215444ABJan 06, 2022
COLCHICINEHETERO LABS LTD VANDA 208993ABAug 13, 2021
COLCHICINEPH HEALTHANDA 203976ABAug 12, 2021
COLCHICINEGRANULESANDA 210425ABFeb 05, 2020
COLCHICINE×2ZYDUS PHARMSANDA 211519Nov 14, 2019
COLCHICINEMYLANANDA 209470ABSep 16, 2019
COLCHICINEDR REDDYSANDA 209876ABSep 06, 2019
COLCHICINEWATSON LABS INCANDA 204461ABJul 31, 2019
COLCHICINEALKEM LABS LTDANDA 211250ABFeb 08, 2019
COLCHICINEPH HEALTHANDA 208678ABNov 29, 2018
COLCHICINEAMNEAL PHARMSANDA 204711ABSep 28, 2016

Listed patents (41)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7964647Oct 06, 2028in 2 yr 4 mo
U-1007
8093297Oct 06, 2028in 2 yr 4 mo
U-1161
8097655Oct 06, 2028in 2 yr 4 mo
U-1020
8415396Oct 06, 2028in 2 yr 4 mo
U-1007
8093296Oct 06, 2028in 2 yr 4 mo
U-1007
8093298Oct 06, 2028in 2 yr 4 mo
U-1116
8415395Oct 06, 2028in 2 yr 4 mo
U-1007
7981938Oct 06, 2028in 2 yr 4 mo
U-1166
7964648Oct 06, 2028in 2 yr 4 mo
U-1161
7619004Dec 03, 2028in 2 yr 6 mo
U-1020
7935731Dec 03, 2028in 2 yr 6 mo
U-1116
7601758Feb 10, 2029in 2 yr 8 mo
U-1007
7820681Feb 17, 2029in 2 yr 8 mo
U-1020
7915269Feb 17, 2029in 2 yr 8 mo
U-1007
8440722Feb 17, 2029in 2 yr 8 mo
U-1020
7906519Feb 17, 2029in 2 yr 8 mo
U-1116
8440721Feb 17, 2029in 2 yr 8 mo
U-1007
9555029Aug 22, 2033in 7 yr 3 mo
U-1020
9789108Aug 22, 2033in 7 yr 3 mo
U-1020
9675613Aug 22, 2033in 7 yr 3 mo
U-1020
8927607Aug 22, 2033in 7 yr 3 mo
U-1020
9399036Aug 22, 2033in 7 yr 3 mo
U-1020
12364675Nov 01, 2033in 7 yr 6 mo
U-3639
12233035Nov 01, 2033in 7 yr 6 mo
U-4132
11026901Nov 01, 2033in 7 yr 6 mo
U-3638
11026900Nov 01, 2033in 7 yr 6 mo
U-3639
11026899Nov 01, 2033in 7 yr 6 mo
U-3639
10842762Nov 01, 2033in 7 yr 6 mo
U-3640
10265281Nov 01, 2033in 7 yr 6 mo
U-3639
10206891Nov 01, 2033in 7 yr 6 mo
U-3641
9744144Nov 01, 2033in 7 yr 6 mo
U-3643
11944594Nov 01, 2033in 7 yr 6 mo
U-3864
12280025Nov 01, 2033in 7 yr 6 mo
U-4168
11944595Nov 01, 2033in 7 yr 6 mo
U-3867
10130585May 09, 2034in 8 yr
U-3642
12274751Nov 22, 2036in 10 yr 7 mo
U-2814
12514819Nov 22, 2036in 10 yr 7 mo
U-2814
10383820Nov 22, 2036in 10 yr 7 mo
ProductU-2814
10383821Nov 22, 2036in 10 yr 7 mo
Product
9907751Nov 22, 2036in 10 yr 7 mo
Product
10226423Dec 20, 2037in 11 yr 8 mo
Product

Colchicine — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.